PETALUMA, Calif., March 09, 2018 (GLOBE NEWSWIRE) -- Sonoma Pharmaceuticals, Inc. (Nasdaq:SNOA, Warrants – SNOAW) today
announced that Jim Schutz, Sonoma CEO, will be a featured presenter at the Roth Capital Partners 30th Annual Growth Stock
Conference on Tuesday, March 13, 2018 at 3:00 pm PDT in yellow salon 6 at the Ritz-Carlton in Laguna Niguel, California.
Mr. Schutz will provide an overview of the company’s business model and growth strategy and will be available for one-on-one
meetings. Interested investors may request a meeting time via oneononerequests@roth.com, or contacting Bob Miller of Sonoma Pharmaceuticals either by calling
925-787-6218 or emailing bmiller@sonomapharma.com.
About Sonoma Pharmaceuticals
Sonoma Pharmaceuticals is a specialty pharmaceutical company that develops and markets solutions for the treatment of
dermatological conditions and advanced tissue care. The company’s products, which are sold throughout the United States and
internationally, have improved outcomes for more than five million patients globally by reducing infections, itch, pain,
scarring and harmful inflammatory responses. The company's headquarters are in Petaluma, California, with manufacturing
operations in the United States and Latin America. European marketing and sales are headquartered in Roermond, Netherlands.
More information can be found at www.sonomapharma.com.
Forward-Looking Statements
Except for historical information herein, matters set forth in this press release are forward-looking within the meaning of
the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, including statements about the commercial and
technology progress and future financial performance of Sonoma Pharmaceuticals, Inc. and its subsidiaries (the “Company”).
These forward-looking statements are identified by the use of words such as “believe,” “achieve,” and “strive,” among others.
Forward-looking statements in this press release are subject to certain risks and uncertainties inherent in the Company’s business
that could cause actual results to vary, including such risks that regulatory clinical and guideline developments
may change, scientific data may not be sufficient to meet regulatory standards or receipt of required regulatory clearances or
approvals, clinical results may not be replicated in actual patient settings, protection offered by the
Company’s patents and patent applications may be challenged, invalidated or circumvented by its competitors, the
available market for the Company’s products will not be as large as expected, the Company’s products will not
be able to penetrate one or more targeted markets, revenues will not be sufficient to fund further development and clinical
studies, as well as uncertainties relative to varying product formulations and a multitude of diverse regulatory and
marketing requirements in different countries and municipalities, and other risks detailed from time to time in the Company’s
filings with the Securities and Exchange Commission. The Company disclaims any obligation to update these forward-looking
statements, except as required by law.
Sonoma Pharmaceuticals® is a registered trademark of Sonoma Pharmaceuticals, Inc. All other trademarks and service marks are the
property of their respective owners.
Media and Investor Contact:
Sonoma Pharmaceuticals, Inc.
Dan McFadden
VP of Public and Investor Relations
(425) 753-2105
dmcfadden@sonomapharma.com